Naghibi Zahra, Rakhshandeh Hassan, Jarahi Lida, Hosseini Seyed Mousalreza, Yousefi Mahdi
Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.
Avicenna J Phytomed. 2021 Mar-Apr;11(2):154-167.
There are several studies reporting the therapeutic effects of on liver diseases. This study was done with the purpose of examining the effect of oxymel (BO) in patients with refractory primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), who did not respond to current treatment.
Patients with PSC or PBC who were receiving ursodeoxycholic acid (UDCA, 13-15 mg/kg/day) for at least six months, but their serum levels of alkaline phosphatase (ALP) were still 1.5 folds higher than the normal upper limit during the last six months, were asked to participate in this quasi-experimental study. Patients were asked to take 0.5 ml/kg/day of BO two times a day for three months along with UDCA. At the end of the study, serum levels of ALP, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), total bilirubin (TB), direct bilirubin (DB), and creatinine as well as prothrombin time (PT), international normalized ratio (INR) and quality of life (QOL) based on PBC-40 questionnaire were assessed as outcomes.
Our results showed that BO notably attenuated the serum levels of ALP, AST, ALT, GGT, TB, and DB, as well as PT and INR and significantly improved QOL.
For first time, we showed that additional therapy with BO has a promising effect in the treatment of refractory PSC and PBC.
有多项研究报道了[具体物质]对肝脏疾病的治疗效果。本研究旨在考察苦胆汁（BO）对当前治疗无反应的难治性原发性硬化性胆管炎（PSC）和原发性胆汁性胆管炎（PBC）患者的疗效。
邀请正在接受熊去氧胆酸（UDCA，13 - 15 mg/kg/天）治疗至少6个月，但在过去6个月期间其血清碱性磷酸酶（ALP）水平仍比正常上限高1.5倍的PSC或PBC患者参与这项准实验研究。要求患者在服用UDCA的同时，每天分两次服用0.5 ml/kg/天的BO，持续三个月。在研究结束时，评估血清ALP、天冬氨酸转氨酶（AST）、丙氨酸转氨酶（ALT）、γ-谷氨酰转移酶（GGT）、总胆红素（TB）、直接胆红素（DB）和肌酐水平，以及凝血酶原时间（PT）、国际标准化比值（INR）和基于PBC - 40问卷的生活质量（QOL）作为研究结果。
我们的结果表明，BO显著降低了血清ALP、AST、ALT、GGT、TB和DB水平，以及PT和INR，并显著改善了QOL。
我们首次表明，BO辅助治疗对难治性PSC和PBC的治疗具有显著效果。
